Acadia Pharmaceuticals Inc (ACAD)’s financial ratios: A comprehensive overview

After finishing at $27.76 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $28.15, up 1.40%. In other words, the price has increased by $+0.39 from its previous closing price. On the day, 1427630 shares were traded. ACAD stock price reached its highest trading level at $28.47 during the session, while it also had its lowest trading level at $27.56.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.


Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $40 from $31 previously.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 08 when DAVIS STEPHEN sold 3,732 shares for $29.96 per share. The transaction valued at 111,811 led to the insider holds 96,521 shares of the business.

Teehan Brendan sold 731 shares of ACAD for $21,901 on Jan 08. The EVP, COO, Head of Commercial now owns 30,949 shares after completing the transaction at $29.96 per share. On Jan 08, another insider, KIM AUSTIN D., who serves as the EVP,General Counsel, Secretary of the company, sold 590 shares for $29.96 each. As a result, the insider received 17,676 and left with 46,901 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 4.62B and an Enterprise Value of 4.33B. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.31 while its Price-to-Book (P/B) ratio in mrq is 12.74. Its current Enterprise Value per Revenue stands at 6.86 whereas that against EBITDA is -28.89.

Stock Price History:

Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $17.71. The 50-Day Moving Average of the stock is 26.12, while the 200-Day Moving Average is calculated to be 24.87.

Shares Statistics:

The stock has traded on average 1.75M shares per day over the past 3-months and 1.62M shares per day over the last 10 days, according to various share statistics. A total of 164.18M shares are outstanding, with a floating share count of 163.05M. Insiders hold about 0.69% of the company’s shares, while institutions hold 96.23% stake in the company. Shares short for ACAD as of Dec 28, 2023 were 7.91M with a Short Ratio of 7.91M, compared to 7.73M on Nov 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.82% and a Short% of Float of 6.45%.

Earnings Estimates

Its stock is currently analyzed by ACADIA Pharmaceuticals Inc. different market analysts. The consensus estimate for the next quarter is $65.33, with high estimates of $0.01 and low estimates of $1.54.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular